BioCryst Pharmaceuticals, Inc. (BCRX), a biotechnology company, on Monday announced the appointment of Babar Ghias as Chief Financial Officer and Head of corporate development.
Ghias has been working as CFO since 2022 at AvenCell Therapeutics.
Chief Executive Officer Jon Stonehouse said the addition of these skills and expertise to the leadership team is exactly what we need at this time.
In the pre-market trading, BioCryst Pharmaceuticals is 0.45% lesser at $8.90 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.